Vaccine-based clinical trials in ovarian cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol.16(Suppl. 8), VIII7–VIII12 (2005).
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med.334(1), 1–6 (1996).
   PubMed Web of Science ®Google Scholar
• Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. J. Epidemiol. Biostat.6(1), 107–138 (2001).
   PubMedGoogle Scholar
• Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA102(51), 18538–18543 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Leffers N, Gooden MJ, de Jong RA et al. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother.58(3), 449–459 (2009).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N. Engl. J. Med.358(25), 2704–2715 (2008).
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy.2(2), 213–226 (2010).
   PubMed Web of Science ®Google Scholar
• Nijman HW, Lambeck A, van der Burg SH, van der Zee AG, Daemen T. Immunologic aspect of ovarian cancer and p53 as tumor antigen. J. Transl. Med.3, 34 (2005).
   PubMed Web of Science ®Google Scholar
• Vermeij R, Daemen T, de Bock GH et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin. Dev. Immunol.2010, 891505 (2010).
   PubMedGoogle Scholar
• Zhang S, Zhou X, Yu H, Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer10, 163 (2010).
   PubMed Web of Science ®Google Scholar
• Odunsi K, Jungbluth AA, Stockert E et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res.63(18), 6076–6083 (2003).
   PubMed Web of Science ®Google Scholar
• Hu XF, Yang E, Li J, Xing PX. MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert. Rev. Anticancer Ther.6(8), 1261–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Odunsi K. Immunologic approaches to ovarian cancer treatment. J. Clin. Oncol.25(20), 2884–2893 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer8(4), 299–308 (2008).
   PubMed Web of Science ®Google Scholar
• Cannon MJ, O’Brien TJ. Cellular immunotherapy for ovarian cancer. Expert. Opin. Biol. Ther.9(6), 677–688 (2009).
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Parker LL et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res.12(20 Pt 1), 6106–6115 (2006).
   PubMed Web of Science ®Google Scholar
• Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov. Med.9(44), 62–70 (2010).
   PubMedGoogle Scholar
• Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin. Immunol.22(3), 132–143 (2010).
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Gnjatic S, Sabbatini P et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res.14(9), 2740–2748 (2008).
   PubMedGoogle Scholar
• Herrin V, Behrens RJ, Achtar M et al. Wild-type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinoma. Presented at: 39th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May–1 June 2003.
   Google Scholar
• Herrin VE, Achtar MS, Steinberg SM et al. A randomized Phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide-pulsed dendritic cells in high risk ovarian cancer patients. Presented at:43rd American Society of Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2007.
   Google Scholar
• Chianese-Bullock KA, Irvin WP Jr, Petroni GR et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J. Immunother.31(4), 420–430 (2008).
   PubMed Web of Science ®Google Scholar
• Tsuda N, Mochizuki K, Harada M et al. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J. Immunother.27(1), 60–72 (2004).
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Qian F, Tsuji T et al. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination. J. Immunol.176(10), 6340–6346 (2006).
   PubMedGoogle Scholar
• Odunsi K, Qian F, Matsuzaki J et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA104(31), 12837–12842 (2007).
   PubMed Web of Science ®Google Scholar
• Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med.358(25), 2698–2703 (2008).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Phase I immunotherapeutic trial with long peptides spanning the e6 and e7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res.14(1), 169–177 (2008).
   PubMed Web of Science ®Google Scholar
• Welters MJ, Kenter GG, Piersma SJ et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res.14(1), 178–187 (2008).
   PubMed Web of Science ®Google Scholar
• Speetjens FM, Kuppen PJK, Welters MJP et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res.15(3), 1086–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med.361(19), 1838–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Leffers N, Lambeck AJ, Gooden MJ et al. Immunization with a p53 synthetic long peptide vaccine induces p53-specific immune responses in ovarian cancer patients, a Phase II trial. Int. J. Cancer125(9), 2104–2113 (2009).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Bijker MS, Welters MJP, Offringa R, Melief CJM. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv. Drug Deliv. Rev.58(8), 916–930 (2006).
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer8(5), 351–360 (2008).
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol. Rev.220, 129–150 (2007).
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood96(9), 3102–3108 (2000).
   PubMed Web of Science ®Google Scholar
• Menon AG, Kuppen PJ, van der Burg SH et al. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther.10(7), 509–517 (2003).
   PubMed Web of Science ®Google Scholar
• van der Burg SH, Menon AG, Redeker A et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res.8(5), 1019–1027 (2002).
   PubMed Web of Science ®Google Scholar
• de Mare A, Lambeck AJ, Regts J et al. Viral vector-based prime–boost immunization regimens: a possible involvement of T-cell competition. Gene Ther.15(6), 393–403 (2008).
   PubMed Web of Science ®Google Scholar
• Lambeck AJ, Nijman HW, Hoogeboom BN et al. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine28(26), 4275–4282 (2010).
   PubMedGoogle Scholar
• Odunsi K, Rodabaugh K, Lele S et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+ and CD8+ anti tumor immune responses in patients with ovarian cancer. Presented at: 38th Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer. San Diego, CA, USA, 3–7 March 2007.
   Google Scholar
• Gulley JL, Arlen PM, Tsang KY et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res.14(10), 3060–3069 (2008).
   PubMed Web of Science ®Google Scholar
• Mohebtash M, Madan R, Tsang K et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. Presented at: 100th American Association for Cancer Research Annual Meeting. Denver, CO, USA, 18–22 April 2009.
   Google Scholar
• Freedman RS, Kudelka AP, Verschraegen CF et al. Therapeutic anti-cancer vaccine: a randomized doule blind dose comparison study of sialyl Tn-KLH with Detox-B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). Presented at: 34th American Society of Clinical Oncology Annual Meeting. Los Angeles, CA, USA, 17–19 May 1998.
   Google Scholar
• MacLean GD, Bowen-Yacyshyn MB, Samuel J et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J. Immunother.11(4), 292–305 (1992).
   PubMed Web of Science ®Google Scholar
• MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis Tumor Immunol.19(1), 59–68 (1996).
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Kudryashov V, Ragupathi G et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a Phase 1 trial. Int. J. Cancer87(1), 79–85 (2000).
   PubMed Web of Science ®Google Scholar
• Sabbatini PJ, Ragupathi G, Hood C et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res.13(14), 4170–4177 (2007).
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Oparin DV, Holmberg LA et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J. Immunother.22(1), 54–66 (1999).
   PubMed Web of Science ®Google Scholar
• Wagner U. Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma12(5), 521–528 (1993).
   PubMedGoogle Scholar
• Wagner U, Reinsberg J, Schmidt S et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophys.24–25, 237–242 (1994).
   PubMedGoogle Scholar
• Berlyn KA, Schultes B, Leveugle B et al. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin. Immunol.101(3), 276–283 (2001).
   PubMed Web of Science ®Google Scholar
• Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int. J. Oncol.32(6), 1145–1157 (2008).
   PubMed Web of Science ®Google Scholar
• Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J. Immunother. Emphasis Tumor Immunol.15(1), 42–52 (1994).
   PubMed Web of Science ®Google Scholar
• Pfisterer J, du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A Phase I trial of the AGO-OVAR. Ann. Oncol.17(10), 1568–1577 (2006).
   PubMed Web of Science ®Google Scholar
• Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (Phase Ib/II). Clin. Cancer Res.10(5), 1580–1587 (2004).
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Dupont J, Aghajanian C et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin. Cancer Res.12(18), 5503–5510 (2006).
   PubMed Web of Science ®Google Scholar
• Berek JS, Ehlen TG, Gordon A et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. Presented at: 37th American Society of Clinical Oncology Annual Meeting. San Francisco, CA, USA, 12–15 May 2001.
   Google Scholar
• Berek JS, Taylor PT, Gordon A et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol.22(17), 3507–3516 (2004).
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol.27(3), 418–425 (2009).
   PubMed Web of Science ®Google Scholar
• Braly P, Nicodemus CF, Chu C et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized Phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J. Immunother.32(1), 54–65 (2009).
   PubMed Web of Science ®Google Scholar
• Ehlen TG, Hoskins PJ, Miller D et al. A pilot Phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer15(6), 1023–1034 (2005).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Schultes BC, Gallion H et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol. Oncol.94(2), 340–351 (2004).
   PubMed Web of Science ®Google Scholar
• Schultes BC, Baum RP, Niesen A, Noujaim AA, Madiyalakan R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol. Immunother.46(4), 201–212 (1998).
   PubMed Web of Science ®Google Scholar
• Nicholson S, Bomphray CC, Thomas H et al. A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother.53(9), 809–816 (2004).
   PubMed Web of Science ®Google Scholar
• Strohlein MA, Siegel R, Jager M et al. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res.28, 18 (2009).
   PubMed Web of Science ®Google Scholar
• Zanten-Przybysz I, Molthoff C, Gebbinck JK et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J. Cancer Res. Clin. Oncol.128(9), 484–492 (2002).
   PubMedGoogle Scholar
• Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. J. Immunother.31(2), 207–214 (2008).
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Berek JS, Casado A et al. Abagovomab maintenance therapy in patients with epithelial ovarian cacner after complete response (CR) post-first-line chemotherapy (FLCT): preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial. Presented at: 46th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 4–8 June 2010.
   Google Scholar
• Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res.14(11), 3536–3544 (2008).
   PubMed Web of Science ®Google Scholar
• Laheru D, Lutz E, Burke J et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res.14(5), 1455–1463 (2008).
   PubMed Web of Science ®Google Scholar
• Chu CS, Boyer J, Coukos G et al. Autologous denritic cell (IDD-6) vaccination as consolidation for advanced ovarian cancer. Presented at: 39th Society of Gynecologic Oncologists Annual Meeting on Women’s cancer. Tampa, FL, USA, 9–12 March 2007.
   Google Scholar
• Britten CM, Gouttefangeas C, Welters MJ et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother.57(3), 289–302 (2008).
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM. Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J. Transl. Med.8, 130 (2010).
   PubMedGoogle Scholar
• Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res.12(3 Pt 1), 878–887 (2006).
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol.13(3), 176–181 (2003).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med.363(14), 1324–1334 (2010).
   PubMed Web of Science ®Google Scholar
• Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene27(2), 168–180 (2008).
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Facciabene A, Kim S et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med.14(1), 28–36 (2008).
   PubMed Web of Science ®Google Scholar
• Croci DO, Zacarias Fluck MF, Rico MJ et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother.56(11), 1687–1700 (2007).
   PubMed Web of Science ®Google Scholar
• Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin. Cancer Res.14(14), 4385–4391 (2008).
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene27(45), 5904–5912 (2008).
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol.5(4), 194–204 (2008).
   PubMedGoogle Scholar
• Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA100(8), 4712–4717 (2003).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Butler M, Oble DA et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA105(8), 3005–3010 (2008).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMed Web of Science ®Google Scholar